Author

Ahmet Kürşad Dişli

Observed names: A.K. Disli, Ahmet K Disli, Ahmet K. Dişli, Ahmet Kursad Disli, Ahmet Kursat Disli, Ahmet Kursat Dıslı, Ahmet Kürsad Disli, Ahmet Kürşad DİŞLİ, Dişli, Ahmet Kürşad

Institutions: Kirsehir Training and Research Hospital, Erciyes University

Observed institutions: Kirsehir Training and Research Hospital, Erciyes University

ORCID: 0000-0001-8014-4140

Observed ORCID: 0000-0001-8014-4140

OpenAlex ID: A5093900117

Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

2024 · Salih Tünbekici, Haydar cagatay Yuksel, et al. · Cancers · 13

PDF

2025 · Taha Koray Sahin, Fatih Atalah, et al. · Frontiers in Immunology · 4

PDF

Prognostic impact of elevated C-reactive protein and procalcitonin in patients with extensive-stage small cell lung cancer

2024 · İrfan Buğday, Mevlüde İnanç, et al. · Anti-Cancer Drugs · 4

Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

2025 · Gökhan Şahin, Esmanur Kaplan Tüzün, et al. · International Journal of Cancer · 2

Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy

2025 · İrfan Buğday, Mevlüde İnanç, et al. · BMC Cancer · 1

PDF

Evaluation of digit ratio (2D:4D) in breast cancer patients

2024 · Şafak Yıldırım Dişli, Ali Caner Özdöver, et al. · Scientific Reports · 1

Receptor Status Changes, HER2-Low Discordance, and TNBC Transformation in Metastatic Breast Cancer: Prognostic Significance and Impact on Survival Outcomes

2026 · Ayşe Nuransoy Cengiz, Muhammet Cengiz, et al. · Journal of Clinical Medicine

Association Between Body Mass Index and Treatment Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

2026 · Ahmet Kürşad Dişli, Ayşe Nuransoy Cengiz, et al. · Cancers

The role of the prognostic nutritional index at baseline and follow-up in patients with metastatic prostate cancer

2026 · Muhammet Cengiz, Ayşe Nuransoy Cengiz, et al. · Discover Oncology

Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey

2026 · Ahmet Kürşad Dişli, Bekir Mert Durukan, et al. · Medicina

PDF

Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers

2026 · Gökhan Şahin, Ahmet Kürşad Dişli, et al. · Medicina

PDF

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

2026 · Mustafa Seyyar, Ali Kalem, et al. · Current Oncology

PDF

430P Efficacy of CDK4/6 inhibitors in BRCA-mutated HR+/HER2- metastatic breast cancer: Turkish Oncology Group (TOG) study

2026 · M. Seyyar, A. Kalem, et al. · ESMO Open

PDF

Prognostic Significance of Skin Toxicity in Patients with Ras Wild-Type Metastatic Colorectal Cancer Treated with Anti-Egfr Monoclonal Antibodies

2026 · Ridvan Gonul, Oktay Bozkurt, et al. · Journal of Clinical Medicine

PDF

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

2026 · Sedat Yıldız, Hacer Demir, et al. · Journal of Clinical Medicine

PDF

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

2025 · Bilgeşah Kılıçtaş, Murat Araz, et al. · Journal of Chemotherapy

2025 · Hasan Çagri Yildirim, Safak Yildirim Disli, et al. · The Breast

Prognostic Factors in Metastatic Urothelial Carcinoma Treated Without Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC): A Single-Center Retrospective Study

2025 · Irfan Bugday, Mevlude Inanc, et al. · Cureus

PDF

2651P Real-world comparison of Cabozantinib and Sunitinib in advanced non–clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (TOG)

2025 · G. Sahin, E. Kaplan Tüzün, et al. · Annals of Oncology

2836P The effect of ribociclib dose reduction on progression-free survival in hormone receptor positive and HER-2 negative metastatic breast cancer: A multicenter study

2025 · M. Artac, A. Oruç, et al. · Annals of Oncology

2025 · T.K. Sahin, F. Atalah, et al. · Annals of Oncology

PDF

2025 · Rıdvan Gönül, Ahmet Kürşad Dişli, et al. · SN Comprehensive Clinical Medicine

Second Line Therapies After Tyrosine Kinase Inhibitory in Metastatic Renal Cell Carcinoma

2025 · Ender DOĞAN, Sedat Tarık FIRAT, et al. · Journal of Oncological Sciences

PDF

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

2025 · Kılıçtaş, Bilgeşah, Araz, Murat, et al. · Figshare

Metastatik renal hücreli karsinom tanılı hastalarda sunitinib toksisitesi ile vücut yüzey alanı ve vücut kitle indeksi arasındaki ilişkinin değerlendirilmesi

2024 · Özkan, Metin, Dişli, Ahmet Kürşad, et al. · Erciyes University - AVESIS

Works count: 28

Citation count: 25

H-index: 3

I10-index: 1